
08.05.20 (wired.com)
| Novavax’s coronavirus vaccine generates promising immune response in early trial, data shows. A Phase I trial involving 131 participants for Novavax’s Covid-19 vaccine candidate showed encouraging early results. According to Novavax, the vaccine produced neutralizing antibodies at a higher rate than even those seen in recovered patients. |